Skip to main content

25-02-2022 | ASCO GU 2022 | Conference coverage | Video

Neoadjuvant avelumab plus axitinib active in high-risk RCC


Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps (4:20).

Related content